From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease.
Alzheimer's disease is a complex neurodegenerative disorder with a multifaceted pathogenesis. This fact has long halted the development of effective anti-Alzheimer drugs. Recently, however, basis for a therapeutic strategy based on multi-target-directed ligands has been formed. In this context, dual binding site acetylcholinesterase inhibitors represent a suitable starting point. The rational modification of their structures to provide them with additional biological properties has emerged as a successful approach.
Bolognesi
Maria Laura
ML
Department of Pharmaceutical Sciences, Alma Mater Studiorum, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy. marialaura.bolognesi@unibo.it
Minarini
Anna
A
Rosini
Michela
M
Tumiatti
Vincenzo
V
Melchiorre
Carlo
C
D000544:Alzheimer Disease / Q000188:drug therapy*; D001665:Binding Sites; D002800:Cholinesterase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D016503:Drug Delivery Systems / Q000639:trends; D006801:Humans; D008024:Ligands; D015394:Molecular Structure; D011073:Polyamines / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D002800:Cholinesterase Inhibitors; D008024:Ligands; D011073:Polyamines